24/7 Market News Snapshot 10 October, 2025 – Quoin Pharmaceuticals, Ltd. American Depositary Shares (NASDAQ:QNRX)

October 10, 2025

DENVER, Colo., 10 October, 2025 (www.247marketnews.com) – (NASDAQ:QNRX) are discussed in this article.
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX), a late clinical-stage specialty pharmaceutical firm focused on addressing unmet medical needs in rare diseases, has recently experienced a significant surge in its stock price, reflecting an increase of 76.04% from the previous closing price. As of now, QNRX shares are trading at approximately $14.365, following an impressive opening at $7.84. Trading volumes have reached 1.05 million shares, generating considerable investor interest in the company’s newfound momentum.

Concurrently, Quoin has announced a strategic securities purchase agreement with prominent healthcare-focused institutional investors, expected to facilitate up to $104.5 million in gross proceeds. This funding will primarily support Quoin’s innovative therapies, including its flagship clinical candidate QRX003, targeted for the treatment of Netherton Syndrome. The initial funding of $16.5 million will be augmented by the opportunity to raise an additional $88.0 million through the cash exercise of warrants, contingent upon investor discretion.

The structured financing agreement details the issuance of approximately 1,993,940 American Depositary Shares (ADSs) coupled with warrants for up to 7,975,760 ADSs, priced at $8.25 per share—a premium relative to prior closing values. Involving participation from respected institutional investors including AIGH Capital Management and Soleus Capital, this deal symbolizes a critical advancement for Quoin as it seeks to bolster its clinical development efforts.

The anticipated closing of this financing is set for around October 14, 2025, subject to customary conditions. The proceeds will be directed towards general corporate purposes, operational expenses, and sustaining the clinical development of QRX003, with projections indicating that these funds will support the company’s initiatives through 2027. Quoin Pharmaceuticals steadfastly continues its commitment to innovation, striving to enhance the quality of life for patients grappling with rare health conditions.

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.